10-K · June 15, 2026
Vistagen Therapeutics reported a net loss of $69.7 million for the fiscal year ended March 31, 2026, with a significant increase in research and development expenses, reaching $55.0 million, primarily driven by…
Earnings analysis · 10-Q
VTGN earnings analysis
Filed August 14, 2026 · Our reading of the company's report
The latest report
Revenue of $1.476 million exceeded the $166,670 consensus estimate and EPS of negative $0.30 was better than the negative $0.35 estimate, but the company remains deeply loss-making with a $13.0 million quarterly net…
Read full summary
Revenue of $1.476 million exceeded the $166,670 consensus estimate and EPS of negative $0.30 was better than the negative $0.35 estimate, but the company remains deeply loss-making with a $13.0 million quarterly net loss. Liquidity totaled $31.7 million, yet management concluded that substantial doubt exists about the company’s ability to continue as a going concern beyond twelve months. The Nasdaq bid-price deficiency, need for additional financing, clinical-development uncertainty and pending securities litigation remain material overhangs.
Reported figures
- Earnings per share
- $-0.3
- Gross margin
- 100%
What stood out
-
Revenue Beat Estimates
Revenue was $1.476 million, above the $166,670 consensus estimate, while reported EPS was negative $0.30 versus the negative $0.35 estimate.
-
Large Quarterly Net Loss
The company reported a net loss of $13.0 million for the three months ended June 30, 2026, underscoring continued operating losses.
-
$31.7M Liquidity Balance
Cash, cash equivalents and marketable securities totaled $31.7 million as of June 30, 2026.
-
Workforce Reduction Supports Cash Control
Management stated that a workforce reduction of approximately 20% was implemented in March 2026; the company had 41 full-time employees as of June 30, 2026.
-
Nasdaq Compliance Extension
The company received a Nasdaq compliance extension through February 1, 2027, to regain compliance with the $1.00 minimum closing bid-price requirement.
-
One Securities Lawsuit Dismissed
The Cesario securities action in the Northern District of California was dismissed with prejudice on August 12, 2026.
What to watch
-
Going-Concern Uncertainty
As of August 14, 2026, the company concluded that substantial doubt existed about its ability to continue as a going concern because its $31.7 million of cash, cash equivalents and marketable securities may not fund operations beyond twelve months.
-
Persistent Operating Losses
The company reported a net loss of $13.0 million for the quarter and stated that it expects to continue incurring significant losses for the foreseeable future.
-
Need for Additional Financing
The filing states that the company will need substantial additional capital and may be forced to delay, reduce or terminate development programs if financing is unavailable; equity financing could substantially dilute stockholders.
-
Potential Nasdaq Delisting
The company did not regain Nasdaq's $1.00 minimum bid-price requirement during the initial 180-day period ending August 3, 2026, and must regain compliance by February 1, 2027.
-
Pending Clinical-Trial Litigation
A putative securities class action alleges misleading disclosures concerning the PALISADE-3 Phase 3 trial; the company was required to respond by August 18, 2026, and two related derivative actions remain consolidated and stayed pending resolution of the class action.
-
Reduced Staffing Could Delay Trials
The March 2026 workforce reduction affected approximately 20% of employees, and management warned that loss of institutional knowledge, attrition and inadequate staffing could delay or terminate clinical trials.
Management's outlook
No quantitative revenue or EPS guidance was provided in the filing. Management disclosed uncertainty regarding whether cash, cash equivalents and marketable securities will fund operations beyond twelve months from August 14, 2026.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.